Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Other financing activities (2023 - 2026)

CG Oncology posted quarterly Other financing activities of $47000.0 for Q1 2026, down 79.74% year-on-year from $232000.0 in Q1 2025, and down 92.07% on a QoQ basis from $593000.0 in Q4 2025.

CG Oncology (CGON) has 4 years of Other financing activities data on file, last reported at $47000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Other financing activities fell 79.74% year-over-year to $47000.0; the trailing twelve-month figure through Mar 2026 stood at $131000.0 (down 98.14% YoY), and the FY2025 full-year result was $316000.0, down 90.77% from the prior year.
  • Other financing activities for Q1 2026 stood at $47000.0, down from $593000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $6.8 million in Q4 2024 and bottomed at -$3.4 million in Q1 2024.
  • The 4-year median for Other financing activities is $232000.0 (2025), against an average of $830888.9.
  • Peak annual rise in Other financing activities reached 106.85% in 2025, while the deepest fall reached 2005.41% in 2025.
  • A 4-year view of Other financing activities shows it stood at $3.7 million in 2023, then soared by 85.53% to $6.8 million in 2024, then plunged by 91.34% to $593000.0 in 2025, then slumped by 92.07% to $47000.0 in 2026.
  • The last three Other financing activities figures came in at $47000.0 (Q1 2026), $593000.0 (Q4 2025), and $270000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 CG Oncology 5.01 Bn 5.01 Bn -1.88 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 47,000.00
Mar 31, 2026 47,000.00
Dec 31, 2025 593,000.00
Dec 31, 2025 593,000.00
Sep 30, 2025 270,000.00
Sep 30, 2025 270,000.00
Jun 30, 2025 -779,000.00
Jun 30, 2025 -779,000.00
Mar 31, 2025 232,000.00
Mar 31, 2025 232,000.00
Dec 31, 2024 6.85 Mn
Dec 31, 2024 6.85 Mn
Jun 30, 2024 -37,000.00
Jun 30, 2024 -37,000.00
Mar 31, 2024 -3.39 Mn
Mar 31, 2024 -3.39 Mn
Dec 31, 2023 3.69 Mn
Dec 31, 2023 3.69 Mn